Welcome to our dedicated page for Genelux SEC filings (Ticker: GNLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page presents Genelux Corporation (NASDAQ: GNLX) SEC filings, offering insight into how the late clinical-stage biopharmaceutical company reports its activities as it develops oncolytic immunotherapies. Genelux focuses on next-generation oncolytic vaccinia virus immunotherapeutic product candidates, led by Olvi-Vec (olvimulogene nanivacirepvec), and its regulatory disclosures help investors follow governance, financing, and development-related matters.
Key filing types for GNLX include annual and quarterly reports, which discuss research and development efforts, clinical trial status for programs such as the OnPrime/GOG-3076 Phase 3 ovarian cancer trial, the VIRO-25 Phase 2 NSCLC trial, and the Olvi-Vec-SCLC-202 Phase 1b/2 SCLC trial, as well as risk factors and other business information. Definitive proxy statements (DEF 14A) provide details on board structure, director elections, equity incentive plans, and corporate governance practices, including matters submitted to stockholders at annual meetings.
Current reports on Form 8-K can describe material events such as changes to equity compensation terms, option repricing decisions under the company’s equity plans, or other board-approved actions. Registration statements and prospectus supplements associated with underwritten public offerings of common stock outline how Genelux raises capital to fund research and development, clinical trial expenses, and general corporate purposes.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as clinical program disclosures, equity plan changes, and stockholder voting outcomes. Real-time updates from EDGAR, along with access to ownership and compensation information contained in proxy materials and other filings, allow investors to monitor GNLX’s regulatory reporting as it advances its immuno-oncology pipeline.
GENELUX Corp executive Ralph Smalling, Head of Regulatory, reported selling a total of 585 shares of common stock in open-market transactions on March 24 and 25, 2026 at prices of $2.42 and $2.51 per share. According to the disclosure, these sales were made to cover estimated taxes owed in connection with vesting restricted stock units. After these transactions, Smalling directly holds 68,073 shares of GENELUX common stock.
GENELUX Corp Chief Technical Officer sells small share block to cover taxes. Joseph Cappello reported an open-market sale of 906 shares of GENELUX common stock at $2.42 per share on March 24, 2026. According to the disclosure, the shares were sold to cover estimated taxes related to the vesting of restricted stock units. Following this transaction, Cappello directly holds 155,154 shares of GENELUX common stock.
GENELUX Corp senior vice president sells small block of shares for taxes. SVP of Clinical Development Yu Yong sold 906 shares of common stock at $2.42 per share in an open-market transaction to cover estimated taxes from vesting restricted stock units. After this sale, Yu Yong directly holds 144,938 shares.
GENELUX Corp President and CEO Thomas Zindrick reported an open-market sale of 3,582 shares of Common Stock on March 24, 2026 at an average price of $2.42 per share. According to the footnote, the sale was made to cover estimated taxes related to vesting restricted stock units, and he now directly holds 534,849 shares.
Genelux has filed a prospectus supplement to sell up to $100,000,000 of its common stock through an "at-the-market" program with TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on Nasdaq or other trading venues at market prices; TD Cowen may be paid commissions of up to 3.0% of gross proceeds.
The supplement states assumed illustrative math based on a $2.59 per‑share price, showing up to 76,749,183 shares outstanding after sales (based on 38,139,144 shares outstanding as of December 31, 2025). Net proceeds are for general corporate purposes, including research, development, clinical trials, capital expenditures and working capital.
Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC that allows it to sell up to $100,000,000 of common stock through an at-the-market offering program. Shares will be issued from an existing shelf registration and sold on Nasdaq or in other permitted transactions.
Genelux can choose when and whether to sell, and either party may terminate the arrangement by written notice. TD Securities (TD Cowen) will receive up to 3.0% of gross proceeds and certain expenses, while net proceeds are earmarked for general corporate purposes, including research, clinical trials, capital spending, and working capital.
GENELUX Corp director Thomas John reported an open-market sale of 10,000 shares of common stock. The transaction occurred on March 2, 2026 at a weighted average price of $2.8957 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. Following this sale, he directly holds 482,784 shares.
Aladar Szalay filed an amended Schedule 13G reporting beneficial ownership of 3,134,286 shares of Genelux Corp common stock, representing 8.2% of the company. This percentage is based on 38,051,771 shares outstanding as of October 30, 2025, as disclosed in Genelux’s Form 10-Q.
The filing shows 1,149,821 shares with sole voting and dispositive power, mainly through two Szalay family trusts, and 1,984,465 shares with shared voting and dispositive power, held by the Szalay Trust dated August 30, 2021 and the reporting person’s spouse. The event date triggering the filing is December 31, 2025.